
Lyell Immunopharma (LYEL) Stock Forecast & Price Target
Lyell Immunopharma (LYEL) Analyst Ratings
Bulls say
Lyell Immunopharma Inc. has demonstrated a solid financial position with cash, cash equivalents, and marketable securities totaling $320 million, an increase from $297 million in the previous quarter, highlighting effective capital management supported by a recent private placement. The company's product pipeline includes promising candidates such as LYL797, LYL119, and LYL845, showcasing significant potential for expanding treatment options in the solid tumor market through innovative T-cell reprogramming technologies. Additionally, the strong performance of Ronde-cel in the CD19/CD20 CAR-Trace and positive feedback regarding the LYL273 dataset reinforces confidence in the company's ability to capture a leading position in the competitive landscape of cell therapies.
Bears say
Lyell Immunopharma's recent financial report indicates a decline in research and development expenses, dropping to $28.2 million in the third quarter of 2025 from $34.9 million in the previous quarter, highlighting potential concerns about the company’s investment in its development pipeline. The company faces significant risks, including challenges in growing its market share in CAR-T therapies, potential decreases in treatment efficacy, and safety issues that could alter the therapeutic landscape for its candidates. Additionally, the lack of definitive evidence regarding the durability of its key candidate, LYL273, raises concerns about its competitive viability without demonstrable improvements in patient outcomes and toxicity management.
This aggregate rating is based on analysts' research of Lyell Immunopharma and is not a guaranteed prediction by Public.com or investment advice.
Lyell Immunopharma (LYEL) Analyst Forecast & Price Prediction
Start investing in Lyell Immunopharma (LYEL)
Order type
Buy in
Order amount
Est. shares
0 shares